Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks

Dr. Jason Porter talks with OncLive about potential sequencing with antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) for HER2+ #lungcancer.

Porter states, “The TKIs are oral medications that target HER2 specifically and do not require intravenous infusion. Given the ongoing COVID-19 pandemic, the utility of outpatient therapy with the TKIs may be preferrable to trastuzumab deruxtecan. However, response and disease control rates with trastuzumab deruxtecan were impressive, and the ADC does not appear to confer the same toxicities that have been observed with the TKIs.”

Watch the full interview here.